Fig. 1 | Signal Transduction and Targeted Therapy

Fig. 1

From: Randomized, multicenter, open-label trial of autologous cytokine-induced killer cell immunotherapy plus chemotherapy for squamous non-small-cell lung cancer: NCT01631357

Fig. 1

a NCT01631357 CONSORT Flow Diagram. CIK, CIK cell immunotherapy; CT, chemotherapy. b Kaplan–Meier estimates of progression-free survival in the two trial groups assessed by investigator according to Version 1.1 of The Response Evaluation Criteria in Solid Tumors. c Analysis of progression-free survival in prespecified subgroups. d Kaplan–Meier estimates of overall survival in the two trial groups assessed by investigator according to Version 1.1 of The Response Evaluation Criteria in Solid Tumors. e Analysis of overall survival in prespecified subgroups. f Change from baseline in sum of the longest diameters of target lesions in patients in CIK cell immunotherapy plus chemotherapy group, assessed by investigator according to Version 1.1 of The Response Evaluation Criteria in Solid Tumors (N = 45); 1, appearance of new malignant pleural effusion confirmed by pathology at firth effect evaluation; 2, 1 patient died from intestinal obstruction after 1 cycle treatment and not received therapeutic evaluation. g Change from baseline in sum of the longest diameters of target lesions in patients in chemotherapy group, assessed by investigator according to Version 1.1 of The Response Evaluation Criteria in Solid Tumors (N = 45); 3, appearance of new bone metastasis at first effect evaluation; 4, appearance of new liver metastasis at first effect evaluation; 5, 1 patient died from massive hemoptysis after 1 cycle treatment and not received therapeutic evaluation

Back to article page